The US$5.4 billion acquisition of Novartis Animal Health by Elanco has been completed.
Both investments position the company to offer a wider range of products, including Elanco’s flagship brands and a comprehensive portfolio of nearly 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes, food safety and more.
Elanco’s acquisition of Novartis Animal Health brings together two strong companies with a passion for serving the customer,” said Gaynor Hillier, general manager UK and Ireland.
“We will continue to offer the products our customers trust, while significantly investing in the development of new solutions to meet our customers’ greatest unmet needs.
“Going forward, Elanco will significantly increase investment in research and development, bringing greater breadth and depth to an already strong pipeline.”
She added: “We will continually seek innovative ways we can support our customers’ business. With increased technical services that combine our analytic and benchmarking tools with on-the-ground support, we’ll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business.
“The complete integration of the businesses will take time, but Elanco will strive to make the transition seamless. For the foreseeable future, business will continue in much the same way, including product ordering and customer support. Availability and access to products will continue uninterrupted.”
For more information, visit www.elanco.com